X

HCP Login

By logging in to our website you will have full access to its content, including Healthcare Professional resources. Click here to register or login below.

X

Register your interest

Complete this form to register your interest for this meeting and we will get back to you.

Indicates required fields.

X

Reporting Adverse Events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. In the Republic of Ireland information can be found at http://www.hpra.ie. Adverse events should also be reported to Merck Serono Limited - Tel: +44(0)20 8818 7373 or email: medinfo.uk@merckgroup.com.

X

Welcome to Merck Neurology

You may request sponsorship to attend a Merck organised meeting. Merck is committed to supporting the professional development and clinical education of healthcare professionals in MS.

Your request for sponsorship will be reviewed by the Merck Medical team. Upon receipt of your request we will email you within a week to advise timelines for the review of your request. Subject to sponsorship being granted, you will be required to sign a sponsorship agreement.

Indicates required fields.

X

Browser Local Storage Cleared

Your local storage for MerckNeurology.co.uk has been cleared. If you continue to use this website we may continue utilise your browsers local storage.

With over 20 years of experience,13 Rebif® demonstrates rapid and long-lasting clinical benefit.2,3,8,9 To access prescribing information for Rebif® please click here.

Click here to view Rebif® indications and contraindications

If you add up all the time all the people have been taking Rebif® since it was approved, it equals 1.45 million patient-years of therapy13

MySupport Patient Support Programme

Merck aims to provide patients with support while on Rebif®. The MySupport programme provides written information and downloadable resources as well as support from dedicated MySupport nurses.

FIND OUT MORE
VIEW REFERENCES
  1. De Stefano N, et al. J Neurol Sci. 2012;312(1-2):97-101.
  2. PRISMS Study Group. Lancet. 1998;352(9139):1498-1504.
  3. Kappos L, et al. J Neurol Neurosurg Psychiatry. 2015; 86(11):1202-1207.
  4. Kozma C, et al. Presented at AAN. April 15–21, 2016, Vancouver Canada. Poster P6.178.
  5. Panitch H, et al. EVIDENCE Study Group. Neurology. 2002;59(10):1496-1506.
  6. De Stefano N, et al. Mult Scler. 2010;16(7):888-892.
  7. Comi G, et al. Lancet Neurol. 2012;11(1):33-41.
  8. PRISMS Study Group. Neurology. 2001;56(12):1628-36.
  9. Kappos L, et al. Neurology. 2006 Sep 26;67(6):944-53.
  10. Sandberg-Wollheim W, et al. Mult Scler. 2011;17(4):431-40.
  11. De Stefano N, et al. J Neurol Neurosurg Psychiatry. 2014:85;647-653.
  12. Rebif® EU summary of product characteristics.
  13. Merck. Data on file (UKDOFREB160002).